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ABSTRACT
Introduction: The purpose of this study was to
evaluate clinical outcomes and drug/
administration costs of treatment with tumor
necrosis factor inhibitor (TNFi) agents in US
veterans with rheumatoid arthritis (RA)
initiating TNFi therapy. The analysis compared
patients initiating and continuing a single TNFi
with patients who subsequently switched to a
different TNFi.
Methods: Data from patients enrolled in the
Veterans Affairs Rheumatoid Arthritis (VARA)
registry who initiated treatment with
adalimumab, etanercept, or infliximab from
2003 to 2010 were analyzed. Outcomes
included duration of therapy, Disease Activity
Score based on 28 joints (DAS28), and direct
drug and drug administration costs.
Results: Of 563 eligible patients, 262 initiated a
single TNFi therapy, 142 restarted their initial
TNFi after a C90-day gap in treatment
(interrupted therapy), and 159 switched to a
different TNFi. Patients who switched had
higher mean DAS28 before starting TNFi
therapy than patients with single or
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interrupted therapy: 5.3 vs 4.5 or 4.6,
respectively. Mean duration of the first course
was 34.3 months for single therapy,
18.3 months for interrupted therapy, and
17.7 months for switched therapy. Mean
post-treatment DAS28 was highest for patients
who switched TNFi. Mean annualized costs for
first course were $13,800 for single therapy,
$13,200 for interrupted therapy, and $14,200
for switched therapy; mean annualized costs for
second course were $12,800 for interrupted
therapy and $15,100 for switched therapy.
Conclusion: Patients who switched TNFi had
higher pre-treatment DAS28 and higher overall
costs than patients who received the same TNFi
as either single or interrupted therapy.
Funding: This research was funded by
Immunex Corp., a fully owned subsidiary of
Amgen Inc., and by VA HSR&D Grant SHP
08-172.
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INTRODUCTION
Tumor necrosis factor inhibitors (TNFi) are
effective therapies for controlling the signs
and symptoms and reducing progression of
erosive disease in many patients with
moderate-to-severe rheumatoid arthritis (RA)
[1, 2]. The most commonly used TNFi agents
approved by the US Food and Drug
Administration for the treatment of
moderate-to-severe RA are adalimumab,
etanercept, and infliximab [3–5]. Adalimumab
and etanercept are self-administered
injectable agents and infliximab is
administered intravenously (IV) [6–8].
Clinicians frequently switch treatment to a
second TNFi agent when patients do not
achieve an adequate response [9–11], lose their
initial response [12], or experience adverse
events with their first course of a TNFi agent
[13, 14].
The use of TNFi agents for the treatment of
RA is associated with significant costs, estimated
to be between $14,000 and $22,000 annually
[4, 5], especially for patients who require dose
escalation to achieve or maintain a clinical
response, which entails 2–44% higher costs
compared with non-dose escalating patients
[15–17]. Additionally, RA is a chronic disease
for which treatment-free remission is rare and
thus requires long-term therapy, adding to the
lifetime cost of treatment. Evaluation of
treatment patterns and associated costs is
important for clinicians to make informed
treatment decisions and for payers to manage
costs; this evaluation is also important
specifically among US veterans with RA
because such an assessment has never been
conducted in this population. Therefore, we
evaluated clinical outcomes and associated
costs in US veterans with RA enrolled in the
Veterans Affairs Rheumatoid Arthritis (VARA)
registry who initiated TNFi therapy after VA
enrollment. This analysis compared disease
activity and drug costs in patients treated with
TNFi agents as a class, rather than comparing
specific agents. The comparison determined
differences between patients who were
persistent on a single TNFi agent and patients
who interrupted therapy with a single TNFi
agent or switched to a different TNFi agent.
Patients were specifically evaluated on duration
of treatment, clinical response, rate of
switching, and drug costs associated with the
initial TNFi treatment episode as well as
subsequent treatment episodes within the VA
health care system.
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METHODS
The VARA Registry
This retrospective, observational study was
based on data obtained from US veterans with
RA who were enrolled in the VARA registry. The
VARA registry is an ongoing, longitudinal,
multicenter registry that included patients
from 12 VA medical centers (Birmingham,
Alabama, USA; Brooklyn, New York, USA;
Dallas, Texas, USA; Denver, Colorado, USA;
Jackson, Mississippi, USA; Iowa City, Iowa,
USA; Little Rock, Arkansas, USA; Omaha,
Nebraska, USA; Portland, Oregon, USA;
Philadelphia, Pennsylvania, USA; Salt Lake
City, Utah, USA; and Washington, DC, USA).
The VARA registry has been described
previously [18, 19].
This study was approved by the University of
Utah Institutional Review Board, the VA
Research Service, and the Scientific and Ethical
Advisory Board of the VARA registry for analysis
of VARA and VA administrative data and was in
compliance with the Helsinki Declaration for
Ethical Principles for Medical Research
Involving Human Subjects of 1964, as revised
in 2013. All patients provided written consent
upon enrollment in the VARA registry.
Patients
All patients met the rheumatologist-confirmed
diagnosis of RA according to the 1987 American
College of Rheumatology criteria [20]. Patients
were eligible to be included in the analysis if
they had enrolled in the VARA registry before
September 30, 2011, and their first TNFi therapy
was initiated between March 17, 2003 (the date
after which all three TNFi agents were available
within the VA), and September 30, 2010, which
allowed the potential for at least 1 year of
observation, ending on September 30, 2011.
To increase the likelihood of evaluating only
patients initiating TNFi therapy within the VA,
patients were required to have at least 6 months
of treatment in the VA before their first TNFi
prescription. Patients were excluded from the
study if they had any TNFi exposure within the
VA before March 17, 2003. Information on
therapy prior to clinical care at the VA was not
available.
Data Sources
Three administrative VA databases [21] were
used in the analysis, including the Corporate
Data Warehouse (CDW) [22], Decision Support
System (DSS) National Pharmacy Extract [23],
and Pharmacy Benefits Management (PBM)
database [24]. Descriptions of these databases
have been previously presented [25]. The
Veterans Health Administration structured
pharmacy data do not completely capture the
dispensing of outpatient drug infusion data.
Furthermore, the barcode medication
administration data only capture medications
administered to inpatients. Therefore, we
conducted a chart review of VA electronic
medical records over the study period to
determine administration of infliximab
through nurse infusion notes. Because some
inconsistencies in the outpatient pharmacy
dispensing data were observed for adalimumab
and etanercept, we developed an algorithm that
integrated information from the three databases
(CDW, DSS, and PBM) and defined each
treatment episode for each patient. The
algorithm reconciled differences between
databases by using information from all data
sources as well as comparing treatment patterns
before and after the discrepancies to estimate
correct dosing [25]. For patients with evidence
of any infliximab infusion from CDW
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(outpatient pharmacy, inpatient unit dose, or
IV package), DSS, or PBM, a complete individual
patient medical record review was completed by
trained chart abstractors over the study period
to characterize infliximab administration events
during the study period.
Study Outcomes
Each dispensing or administration event of a
TNFi agent was used along with information on
quantity dispensed and days supply to construct
individual treatment episodes. The expected
supply (in days) was determined based on
dosing instructions and the number of
syringes or vials that had been dispensed for
injectable agents. For infliximab, each
administration event was determined by
chart abstraction as noted above. Our focus
was limited to the first two drug courses with
TNFi agents during the study period. A drug
course was defined as a period of continuous
TNFi treatment consisting of one or more
treatment episodes without a gap of 90 or
more days between the expected end of that
episode based on days supply and the start of
the subsequent treatment episode. Duration of
treatment course was defined as the time from
the date of first treatment until the date of the
expected end of the last dispensing episode for
the injectable TNFi agents or 8 weeks after the
last infusion (based on the longest
recommended dosing interval in the
prescribing information) for infliximab, for
each course of therapy.
For those patients who were naı¨ve to prior
biologic therapy at the VA, duration of
treatment was calculated for the first and
second course of therapy. Patients with single
therapy had only a first course of treatment,
while patients with interrupted and switched
therapy had both first and second courses of
treatment (Fig. 1). Patients who initiated a
non-biologic TNFi agent were classified as
having a TNFi discontinuation. Subsequent
courses were not evaluated, thus each patient
was classified as having either single
(continuous), interrupted, or switched therapy.
Patients began their second course of treatment
after a gap in treatment of 90 or more days
(interrupted therapy) or initiation of a second
TNFi agent (switched therapy).
Disease activity was assessed by the Disease
Activity Score based on 28 joints (DAS28) [26],
using erythrocyte sedimentation rate as the
laboratory measure of inflammation. DAS28
before starting TNFi therapy was defined as the
mean of all DAS28 values from VARA
enrollment until 30 days after TNFi therapy
start date, with most of these values measured
within the first 5 days of initiating therapy.
Post-treatment DAS28 was the mean of all
DAS28 values beginning 90 days after TNFi
therapy start date to allow time for the
medication to take effect. Changes in DAS28
represent the difference between mean DAS28
before TNFi therapy and mean DAS28 after TNFi
therapy for patients with values at both time
points.
Drug costs and associated administration
costs were calculated using VA PBM prices,
including a Blanket Purchase Agreement price
for adalimumab and a Big 4 price—which is
only available to VA, Department of Defense,
Public Health Service (Indian Health Service),
and US Coast Guard customers [24]—for
etanercept and infliximab [21]. To
approximate the most current drug costs, the
January 1, 2013, to February 28, 2014, Federal
Supply Schedule pricing was used to calculate
adalimumab costs ($506.78 for 40 mg syringes);
September 30, 2012, to September 29, 2017,
pricing was used to calculate etanercept costs
($139.54 for 25 mg syringes and $279.08 for
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50 mg syringes); and January 1, 2013, to
February 29, 2016, pricing was used to
calculate infliximab costs ($456.81 per 100 mg
vial). The administrative cost for each treatment
episode of etanercept and adalimumab was $25
(VA dispensing costs) and for each IV episode of
infliximab was $169.09 (VA infusion costs).
Total drug costs were the sum of the direct
drug costs and the drug administration costs
and are reported as the annualized cost of
treatment by dividing the cost of the
treatment course by the duration of the
treatment course. Costs were calculated for the
first course of TNFi treatment. Subsequent costs
were then evaluated according to the initial
drug assignment and calculated on an
annualized basis. Second-course costs were
based on the TNFi assignment for the agent
that was selected for the second course of
treatment.
Statistical Analysis
Continuous data are presented as means and 95%
confidence intervals (CIs), and dichotomous data
are presented as proportions and 95% CIs. The
focus on CIs instead of P values provides evidence
for the stability of estimates along with statistical
significance testing—when the CIs do not overlap
between two groups then the P values are\0.05
and considered significantly different [27, 28].
The data analysis for this paper was generated
using SAS software version 9.2 (SAS Institute Inc.,
Cary, NC, USA).
Fig. 1 Treatment courses. Patients with RA were
categorized as having undergone single therapy, interrupted
therapy, or switched therapy. Patients in the single and
interrupted therapy categories received one TNFi agent
(‘‘TNFi 1’’) during the observation period, while patients in
the switched therapy category received two TNFi agents
(‘‘TNFi 1’’ and ‘‘TNFi 2’’) during the observation period.
Patients could have undergone only a ﬁrst course of
treatment (i.e., the single therapy patients) or a ﬁrst and
second course (i.e., the interrupted and switched therapy
patients); second courses of treatment began after a
treatment gap 90 or more days (for interrupted therapy
patients) or after initiation of a second TNFi agent (for
switched therapy patients). TNFi tumor necrosis factor
inhibitor, RA rheumatoid arthritis
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RESULTS
Patients
Of 1767 patients in the VARA registry at the
time of analysis, 563 fulfilled the eligibility
criteria to be included in this analysis, including
204 who initiated adalimumab, 290 who
initiated etanercept, and 69 who initiated
infliximab for their first course of TNFi
treatment. The selection of these patients as
part of an analysis of persistence and dose
escalation was previously described [25]. Of
these, 262 patients remained on their initial
TNFi agent during the entire observation period
(single therapy), 142 had a gap of 90 or more
days in therapy and started a second course on
their initial TNFi (interrupted therapy), and 159
started a second course with a different TNFi
(switched therapy) (Fig. 1). The study
population was predominantly male and white
(Table 1). Baseline demographic and clinical
characteristics were similar among patients
with single therapy, interrupted therapy, and
switched therapy. The initial TNFi agents
selected are listed in Table 1.
Average Duration of Drug Courses
The mean duration of single therapy was
34.3 months, which was similar to the
combined mean duration of the first and







Age, mean years (95% CI) 63.1 (61.9–64.3) 57.8 (55.7–59.9) 59.0 (57.5–60.5)
Sex, % men (95% CI) 81 (76–85) 92 (87–96) 91 (86–95)
Race, % (95% CI)
White/Caucasian 79 (73–83) 65 (56–73) 77 (70–83)
Black/African American 15 (11–20) 26 (19–34) 16 (10–22)
Hispanic 3 (1.3–6.0) 4 (1.6–9.0) 5 (2.1–9.7)
American Indian/Paciﬁc Islander 1 (0.2–3.3) 2 (0.4–6.0) 1 (0.15–4.5)
Asian 0 1 (0.2–5.0) 0
Other/unknown 2 (0.6–4.4) 1 (0.2–5.0) 1 (0.15–4.5)
Disease duration, mean years (95% CI) 10.6 (9.3–11.9) 10.9 (9.1–12.7) 9.8 (8.3–11.3)
RF positive, % (95% CI) 79 (74–84) 85 (78–90) 76 (67–82)
Anti-CCP positive, % (95% CI) 75 (66–80) 82 (74–88) 79 (72–85)
Initial TNFi, % of each agent (95% CI)
Adalimumab, n = 204 51 (44–58) 29 (23–36) 20 (15–26)
Etanercept, n = 290 43 (37–49) 24 (19–30) 33 (27–38)
Inﬂiximab, n = 69 46 (34–59) 19 (10–30) 35 (24–47)
TNFi tumor necrosis factor inhibitor, CI conﬁdence interval, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated
peptide antibody
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second course of treatment for patients with
interrupted therapy (34.1 months) and
switched therapy (35.5 months) (Table 2).
Based on nonoverlapping CIs, the 34.3 months
of first-course single therapy was significantly
longer than the 18.3 and 17.7 months for the
first courses for patients who had interrupted
therapy and switched therapy, respectively
(Table 2). The mean duration of the second
course of treatment for patients who restarted
their initial TNFi was 15.8 months, which was
similar to the 17.8 months of the second course
of treatment for patients who switched to a
different TNFi.
Clinical Outcomes
During the observation period before initiation
of the first TNFi treatment course, the average
number of DAS28 measurements and their
associated 95% CIs were 2.1 (1.7–2.5), 4.3
(3.6–4.8), and 3.2 (2.7–3.6) for patients on
single, interrupted, and switched therapy,
respectively. During the first course of therapy,
the average number (95% CI) of DAS28
measurements was 3.8 (3.3–4.3), 2.8 (2.4–3.1),
and 3.6 (3.0–4.1) in the single, interrupted, and
switched therapy groups, respectively. During
the second course of therapy, average number
(95% CI) of DAS28 measurements was 2.8
(2.4–3.1) and 3.6 (3.0–4.1) in the interrupted
and switched therapy groups.
In all groups, post-treatment DAS28 was
significantly lower than DAS28 before starting
TNFi therapy (Table 3). Patients who switched
to a different TNFi for their second course of
treatment had higher mean DAS28 before
initiating TNFi therapy compared with
patients who received single therapy or
interrupted therapy: patients who remained
on a single TNFi agent whether they
underwent single or interrupted therapy had a
pretreatment DAS28 score of 4.53 or 4.56,
respectively, while those who switched had a
pretreatment DAS28 score of 5.3 (Fig. 2). The
change in DAS28 from pre- to post-treatment







First course, mean months (95% CI) 34.3 (30.9, 37.7) 18.3 (15.5, 21.0) 17.7 (14.7, 20.8)
Second course, mean months (95% CI) NA 15.8 (12.9, 18.6) 17.8 (14.9, 20.6)
TNFi tumor necrosis factor inhibitor, CI conﬁdence interval, NA not applicable







Mean difference in DAS28 from pre-treatment
to C90 days after ﬁrst course (95% CI)
-0.9 (-1.2, -0.7) -1.1 (-1.5, -0.6) -0.8 (-1.2, -0.4)
Mean difference in DAS28 during initial course
to C90 days after second course (95% CI)
NA -0.3 (-0.6, 0.0) -0.2 (-0.5, 0.2)
DAS28 Disease activity score based on 28 joints, TNFi tumor necrosis factor inhibitor, CI conﬁdence interval, NA not
applicable
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was similar among patients who remained on
their initial TNFi, restarted their initial TNFi,
and switched TNFi (Fig. 2; Table 3).
Consequently, patients with switched therapy
had higher post-treatment DAS28 than patients
with single therapy and interrupted therapy
(Fig. 2). Responders and non-responders were
included in the analysis, which reduced the
mean improvement in DAS28 (Table 3).
Cost of Treatment
Mean annualized costs for drug and drug
administration for the first course of treatment
were similar among patients who remained on
their initial TNFi, patients who restarted their
initial TNFi, and patients who switched TNFi
(Table 4). Mean annualized costs for the second
course of treatment were highest for patients
who switched to a different TNFi.
DISCUSSION
One goal of this study was to assess clinical
outcomes, duration of treatment, and costs of
treatment associated with TNFi agents as a class
rather than specific agents. Such an analysis
enabled comparison between patients who were
persistent on a single TNFi agent and patients
who interrupted therapy with a single TNFi
agent or switched to a different TNFi agent. Our
findings show that all patients had a similar
Fig. 2 DAS28 before and during the ﬁrst and second
courses of treatment. Mean DAS28 values before the ﬁrst
course of treatment (open bars), mean values during
therapy 90 or more days after the ﬁrst course of treatment
(light gray), and mean values during therapy 90 or more
days after the initiation of the second course of treatment
(dark gray) in patients receiving single therapy (left bars),
interrupted therapy with the same TNFi agent (center
bars), or switched therapy with a second TNFi agent (right
bars) are shown. Error bars represent 95% CI. DAS28,
Disease Activity Score based on 28 joints; TNFi tumor
necrosis factor inhibitor, CI conﬁdence interval
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degree of improvement in disease activity as
measured by DAS28 scores whether they were
persistent on a single TNFi agent with and
without an interruption of therapy or switched
TNFi agents. DAS28 data indicate that the
change in post-treatment disease activity did
not differ significantly among all groups
analyzed—single therapy, interrupted therapy,
and switched therapy. Patients did differ with
regard to DAS28 scores before starting TNFi
therapy, which were higher in patients who
eventually switched therapy than in patients
with single therapy or interrupted therapy. The
absolute disease severity level was higher in
patients who switched TNFi agents. These data
suggest that patients with a higher initial
disease activity are more likely to switch to a
second TNFi agent than patients with a lower
initial disease activity.
Prior reports describing changes in TNFi
therapy have focused on switching between
TNFi agents and have not considered
interrupted therapy. Bonafede et al. reported
rates of 12–25% for interrupted therapy with a
single TNFi agent during the first year of TNFi
therapy based on a 45-day gap in treatment [9],
which was similar to the 25% rate of
interruption in our patients based on a 90-day
gap in treatment; however, their switching rate
was 13%, which was lower than our observed
switching rate of 28%. Scrivo et al. reported a
10% switching rate [29] over a span of
3–47 months, Hyrich et al. and Zhang et al.
both observed a 13% switching rate [11, 30]
over a mean of 15 months, and Virkki et al.
found a 37% switching rate [12] over a mean of
28 months. Schabert et al. reported a low
switching rate of 9–11% in the first year of
treatment [5].
Comparison of our results with those of
other groups who have reported significant
clinical improvement in disease severity when
switching TNFi agents is challenging because of
the differences in methodology and clinical
settings for these studies. Many of these
comparative studies do not have baseline
disease activity assessment during the first
TNFi course. Instead, these analyses compare
the response during the second course of TNFi
treatment to a clinical course during the first
course of TNFi treatment [13, 31, 32]. Others
have reported similar responses with a first and
second TNFi agent with increases in disease
activity in between courses [33]. In some cases,
high persistence rates (71–74%) on second TNFi
agents are reported, but without disease severity
measures [30]. A separate report of US veterans
switching biologics demonstrated that veterans
who switched had a higher DAS28 score before
TNFi therapy than veterans who did not switch
[14]. Virkki et al. and Scrivo et al. emphasized
the benefit of switching TNFi agents when a
secondary loss of efficacy was seen [12, 29]. In
our analysis, the change in clinical response











$13,200 ($12,100, $14,300) $14,200 ($13,700, $14,800)
Second course, mean annualized
cost in USD (95% CI)
NA $12,800 ($12,100, $13,600) $15,100 ($13,700, $16,500)
TNFi tumor necrosis factor inhibitor, USD United States dollars, CI conﬁdence interval, NA not applicable
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with the second TNFi agent from initial baseline
was similar to the response with the initial TNFi
agent. The disease activity during the first and
second courses was similar. This observation
may have represented clinical benefit until the
secondary loss of efficacy occurred. There is
speculation that the development of anti-TNFi
antibodies may play a potential role in these
cases with secondary loss of efficacy [9].
Another goal of our analysis was to compare
costs of TNFi therapy within a drug class
between patients who used a single TNFi agent
and patients who switched TNFi agents. This
work demonstrates that, while the annualized
drug costs of the first course of treatment for
patients who switched TNFi therapy were
slightly higher than the costs of the first
course of treatment in patients who remained
on a single TNFi agent, these cost differences
were not statistically significant. The
annualized costs for patients with interrupted
therapy with a single TNFi agent were similar
for the first and second courses of treatment. In
contrast, the costs for the second course of TNFi
treatment in patients who switched to a second
TNFi agent were significantly higher than those
for the second course of treatment in patients
who had interrupted therapy with a single TNFi
agent. Differences in cost may have been the
result, in part, of differences in disease activity,
which required dose escalation to address this
higher disease activity. The higher costs for
second courses of medication may have been
related to dose escalation during the second
course of treatment, which has been previously
reported [15].
While the use of biologic agents is associated
with significant costs, most analyses report that
these agents fall within a currently accepted
threshold of cost effectiveness [34–37]. Prior
studies have specifically focused on costs per
agent rather than costs of the TNFi therapy
class. These studies have generally
demonstrated that costs for infliximab are
higher than those for injectable agents
[4, 5, 38–40]. We have previously published
that dose escalation is more common with
infliximab in subsequent courses, which is also
associated with higher costs [25].
Strengths of our study included
rheumatologist-confirmed diagnosis of RA in
contrast to the use of administrative data in
many other studies, the wide geographic
distribution of patients across the US, the
collection of baseline and post-treatment
disease severity information using the DAS28,
and standardized medical records and
administrative databases within the VA system
across all participating sites. Veterans enrolled
in VA care have access to TNFi therapy as
needed.
Limitations of the study included a
predominance of men with RA of long-term
duration reflecting the US veteran population,
which may limit the generalizability of these
findings to other populations. This study
population of US Veterans is principally male
and elderly in comparison with most RA
populations that are predominantly female
and of younger age. The demographic
characteristics of the patients in this study
may result in terminating and/or switching
therapy more frequently because of
comorbidities and concurrent medications.
This bias may explain the lower rate of
switching reported in other studies, which
included populations that were younger and
mostly female [5, 9, 11, 30]. The potential exists
that patients may have received TNFi therapy
outside the VA, which would not be captured by
this analysis; however, in our experience, US
veterans rarely seek TNFi therapy from other
sources while receiving their care through the
VA. The federally negotiated cost for TNFi
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therapy in the VA system may be less than costs
in the community, which may limit
comparisons with other systems. Our study
did not identify the reasons for TNFi switching
or interrupting TNFi therapy. Such factors could
confound the observed results. Another
limitation is our lack of evaluation of
background drug-modifying antirheumatic
drug therapy, which may have an impact on
decisions regarding continuation, interruption,
or switching of TNFi therapy. Because of
potential confounding factors inherent to
observational studies, more research is needed
to understand reasons for switching TNFi
therapy and the effects of switching on overall
outcomes in RA.
CONCLUSION
In summary, our data demonstrate that patients
who received TNFi single therapy or interrupted
therapy with a single TNFi agent presented with
a lower level of disease activity than patients
who switched TNFi therapy. The degree of
improvement in disease severity was similar in
all groups. Switching to a different TNFi agent
was associated with higher drug costs when
compared with remaining on the initial
therapy.
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